CMRF-56⁺ blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses

References

• Wimmers F, Schreibelt G, Skold AE, Figdor CG, De Vries IJ. Paradigm shift in dendritic cell-based immunotherapy: from in vitro generated monocyte-derived DCs to naturally circulating DC subsets. Front Immunol 2014; 5:165; PMID:24782868; http://dx.doi.org/10.3389/fimmu.2014.00165
   PubMed Web of Science ®Google Scholar
• Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for cancer therapy. Lancet Oncol 2014; 15:e257-67; PMID:24872109; http://dx.doi.org/10.1016/S1470-2045(13)70585-0
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10:909-15; PMID:15340416; http://dx.doi.org/10.1038/nm1100
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12:265-77; PMID:22437871; http://dx.doi.org/10.1038/nrc3258
   PubMed Web of Science ®Google Scholar
• Fromm P, Gottlieb D, Bradstock KF, Hart DNJ. Cellular therapy to treat haematological and other malignancies: progress and pitfalls. Pathology 2011; 43:605-15; PMID:21897329; http://dx.doi.org/10.1097/PAT.0b013e32834b6b24
   PubMed Web of Science ®Google Scholar
• Anguille S, Smits EL, Bryant C, Van Acker HH, Goossens H, Lion E, Fromm PD, Hart DN, Van Tendeloo VF, Berneman ZN. Dendritic cells as pharmacological tools for cancer immunotherapy. Pharmacol Rev 2015; 67:731-53; PMID:26240218; http://dx.doi.org/10.1124/pr.114.009456
   PubMed Web of Science ®Google Scholar
• Rosenblatt J, Avivi I, Vasir B, Uhl L, Munshi NC, Katz T, Dey BR, Somaiya P, Mills H, Campigotto F et al. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res 2013; 19:3640-8; PMID:23685836; http://dx.doi.org/10.1158/1078-0432.CCR-13-0282
   PubMed Web of Science ®Google Scholar
• Van Driessche A, Van de Velde AL, Nijs G, Braeckman T, Stein B, De Vries JM, Berneman ZN, Van Tendeloo VF. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial. Cytotherapy 2009; 11:653-68; PMID:19530029; http://dx.doi.org/10.1080/14653240902960411
   PubMed Web of Science ®Google Scholar
• Van Tendeloo VF, Van de Velde A, Van Driessche A, Cools N, Anguille S, Ladell K, Gostick E, Vermeulen K, Pieters K, Nijs G et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci USA 2010; 107:13824-9; PMID:20631300; http://dx.doi.org/10.1073/pnas.1008051107
   PubMed Web of Science ®Google Scholar
• Berneman ZN, Van de Velde AL, Willemen Y, Anguille S, Saevels K, Germonpre P, Huizing MT, Peeters M, Snoeckx A, Parizel P et al. Vaccination with WT1 mRNA-electroporated dendritic cells: report of clinical outcome in 66 cancer patients. Blood 2014; 124:310-310
   Web of Science ®Google Scholar
• Lendvai N, Cohen AD, Cho HJ. Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma. Bone marrow transplantation 2015; 50:770-780; PMID:25751647; http://dx.doi.org/10.1038/bmt.2015.5
   PubMed Web of Science ®Google Scholar
• MacDonald KPA, Munster DJ, Clark GJ, Dzionek A, Schmitz J, Hart DNJ. Characterization of human blood dendritic cell subsets. Blood 2002; 100:4512-20; PMID:12393628; http://dx.doi.org/10.1182/blood-2001-11-0097
   PubMed Web of Science ®Google Scholar
• Ding Y, Ju X, Azlan M, Hart DN, Clark GJ. Screening of the HLDA9 panel on peripheral blood dendritic cell populations. Immunology letters 2011; 134:161-6; PMID:20970455; http://dx.doi.org/10.1016/j.imlet.2010.10.010
   PubMed Web of Science ®Google Scholar
• Kassianos AJ, Jongbloed SL, Hart DN, Radford KJ. Isolation of human blood DC subtypes. Methods Mol Biol 2010; 595:45-54; PMID:19941104; http://dx.doi.org/10.1007/978-1-60761-421-0_3
   PubMedGoogle Scholar
• Bachem A, Guttler S, Hartung E, Ebstein F, Schaefer M, Tannert A, Salama A, Movassaghi K, Opitz C, Mages HW et al. Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. J Exp Med 2010; 207:1273-81; PMID:20479115; http://dx.doi.org/10.1084/jem.20100348
   PubMed Web of Science ®Google Scholar
• Kassianos AJ, Hardy MY, Ju X, Vijayan D, Ding Y, Vulink AJ, McDonald KJ, Jongbloed SL, Wadley RB, Wells C et al. Human CD1c (BDCA-1)(+) myeloid dendritic cells secrete IL-10 and display an immuno-regulatory phenotype and function in response to Escherichia coli. Eur J Immunol 2012; 42:1512-22; PMID:22678905; http://dx.doi.org/10.1002/eji.201142098
   PubMed Web of Science ®Google Scholar
• Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Angel CE, Chen CJ, Dunbar PR, Wadley RB, Jeet V et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 2010; 207:1247-60; PMID:20479116; http://dx.doi.org/10.1084/jem.20092140
   PubMed Web of Science ®Google Scholar
• Clark GJ, Kupresanin F, Fromm PD, Ju X, Muusers L, Silveira PA, Elgundi Z, Gasiorowski RE, Papadimitrious MS, Bryant C et al. New insights into the phenotype of human dendritic cell populations. Clinical and Translational Immunology 2015; 5:e61; PMID:26900474; http://dx.doi.org/10.1038/cti.2015.40
   Web of Science ®Google Scholar
• Prue RL, Vari F, Radford KJ, Tong H, Hardy MY, D'Rozario R, Waterhouse NJ, Rossetti T, Coleman R, Tracey C et al. A phase I clinical trial of CD1c (BDCA-1)+ dendritic cells pulsed with HLA-A*0201 peptides for immunotherapy of metastatic hormone refractory prostate cancer. J Immunother 2014; 38:71-6; PMID:25658616; http://dx.doi.org/10.1097/CJI.0000000000000063
   Web of Science ®Google Scholar
• Schreibelt G, Bol KF, Westdorp H, Wimmers F, Aarntzen EH, Duiveman-de Boer T, van de Rakt MW, Scharenborg NM, de Boer AJ, Pots JM et al. Effective clinical responses in metastatic melanoma patients after vaccination with primary myeloid dendritic cells. Clin Cancer Res 2015; 22:2155-66; PMID:26712687; http://dx.doi.org/10.1158/1078-0432.CCR-15-2205
   PubMed Web of Science ®Google Scholar
• Schreibelt G, Klinkenberg LJ, Cruz LJ, Tacken PJ, Tel J, Kreutz M, Adema GJ, Brown GD, Figdor CG, de Vries IJ. The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells. Blood 2012; 119:2284-92; PMID:22234694; http://dx.doi.org/10.1182/blood-2011-08-373944
   PubMed Web of Science ®Google Scholar
• Tel J, Aarntzen EH, Baba T, Schreibelt G, Schulte BM, Benitez-Ribas D, Boerman OC, Croockewit S, Oyen WJ, van Rossum M et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res 2013; 73:1063-75; PMID:23345163; http://dx.doi.org/10.1158/0008-5472.CAN-12-2583
   PubMed Web of Science ®Google Scholar
• Jefford M, Schnurr M, Toy T, Masterman KA, Shin A, Beecroft T, Tai TY, Shortman K, Shackleton M, Davis ID et al. Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuli. Blood 2003; 102:1753-63; PMID:12738673; http://dx.doi.org/10.1182/blood-2002-12-3854
   PubMed Web of Science ®Google Scholar
• Freeman JL, Vari F, Hart DN. CMRF-56 immunoselected blood dendritic cell preparations activated with GM-CSF induce potent antimyeloma cytotoxic T-cell responses. J Immunother 2007; 30:740-8; PMID:17893566; http://dx.doi.org/10.1097/CJI.0b013e31814fb2d6
   PubMed Web of Science ®Google Scholar
• Osugi Y, Vuckovic S, Hart DN. Myeloid blood CD11c(+) dendritic cells and monocyte-derived dendritic cells differ in their ability to stimulate T lymphocytes. Blood 2002; 100:2858-66; PMID:12351396; http://dx.doi.org/10.1182/blood.V100.8.2858
   PubMed Web of Science ®Google Scholar
• Robbins SH, Walzer T, Dembele D, Thibault C, Defays A, Bessou G, Xu H, Vivier E, Sellars M, Pierre P et al. Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profiling. Gen Biol 2008; 9:R17; PMID:18218067; http://dx.doi.org/10.1186/gb-2008-9-1-r17
   PubMed Web of Science ®Google Scholar
• Lindstedt M, Lundberg K, Borrebaeck CAK. Gene family clustering identifies functionally associated subsets of human in vivo blood and tonsillar dendritic cells. J Immunol 2005; 175:4839-46; PMID:16210585; http://dx.doi.org/10.4049/jimmunol.175.8.4839
   PubMed Web of Science ®Google Scholar
• Hemont C, Neel A, Heslan M, Braudeau C, Josien R. Human blood mDC subsets exhibit distinct TLR repertoire and responsiveness. J Leukoc Biol 2013; 93:599-609; PMID:23341538; http://dx.doi.org/10.1189/jlb.0912452
   PubMed Web of Science ®Google Scholar
• Moseman EA, Liang X, Dawson AJ, Panoskaltsis-Mortari A, Krieg AM, Liu YJ, Blazar BR, Chen W. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J Immunol 2004; 173:4433-42; PMID:15383574; http://dx.doi.org/10.4049/jimmunol.173.7.4433
   PubMed Web of Science ®Google Scholar
• Tel J, Lambeck AJ, Cruz LJ, Tacken PJ, de Vries IJ, Figdor CG. Human plasmacytoid dendritic cells phagocytose, process, and present exogenous particulate antigen. J Immunol 2010; 184:4276-83; PMID:20304825; http://dx.doi.org/10.4049/jimmunol.0903286
   PubMed Web of Science ®Google Scholar
• De Vries IJ, Krooshoop DJ, Scharenborg NM, Lesterhuis WJ, Diepstra JH, Van Muijen GN, Strijk SP, Ruers TJ, Boerman OC, Oyen WJ et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 2003; 63:12-7; PMID:12517769
   PubMed Web of Science ®Google Scholar
• Verdijk P, Aarntzen EHJG, Lesterhuis WJ, Boullart ACI, Kok E, van Rossum MM, Strijk S, Eijckeler F, Bonenkamp JJ, Jacobs JFM et al. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res 2009; 15:2531-40; PMID:19318472; http://dx.doi.org/10.1158/1078-0432.CCR-08-2729
   PubMed Web of Science ®Google Scholar
• Clark G, Munster D, Yusuf S, Hart DN. Eighth leucocyte differentiation antigen workshop DC section summary. Cell Immunol 2005; 236:21-8; PMID:16168976; http://dx.doi.org/10.1016/j.cellimm.2005.08.005
   PubMed Web of Science ®Google Scholar
• Mason D, Andre P, Bensussan A, Buckley C, Civin C, Clark E, de Haas M, Goyert S, Hadam M, Hart D et al. CD antigens 2001: aims and results of HLDA workshops. Stem Cells 2001; 19:556-62; PMID:11713348; http://dx.doi.org/10.1634/stemcells.19-6-556
   PubMedGoogle Scholar
• Vremec D. The isolation of mouse dendritic cells from lymphoid tissues and the identification of dendritic cell subtypes by multiparameter flow cytometry. Methods Mol Biol 2010; 595:205-29; PMID:19941115; http://dx.doi.org/10.1007/978-1-60761-421-0_14
   PubMedGoogle Scholar
• Clark G, Stockinger H, Balderas R, van Zelm MC, Zola H, Hart DNJ, Engel P. Nomenclature of CD molecules from the tenth human differentiation leucocyte antigen workshop. Clin Transl Immunol 2016; 5:e57; PMID:26900471; http://dx.doi.org/10.1038/cti.2015.38
   Web of Science ®Google Scholar
• Ohradanova-Repic A, Machacek C, Fischer MB, Stockinger H. Differentiation of human monocytes and derived subsets of macrophages and dendritic cells by the HLDA10 monoclonal antibody panel. Clin Trans Immunol 2016; 5:e55; PMID:26900469; http://dx.doi.org/10.1038/cti.2015.39
   Google Scholar
• Radford KJ, Turtle CJ, Kassianos AJ, Vuckovic S, Gardiner D, Khalil D, Taylor K, Wright S, Gill D, Hart DN. Immunoselection of functional CMRF-56+ blood dendritic cells from multiple myeloma patients for immunotherapy. J Immunother 2005; 28:322-31; PMID:16000950; http://dx.doi.org/10.1097/01.cji.0000163592.66910.e4
   PubMed Web of Science ®Google Scholar
• Lopez JA, Bioley G, Turtle CJ, Pinzûn-Charry A, Ho CSK, Vuckovic S, Crosbie G, Gilleece M, Jackson DC, Munster D et al. Single step enrichment of blood dendritic cells by positive immunoselection. J Immunol Methods 2003; 274:47-61; PMID:12609532; http://dx.doi.org/10.1016/S0022-1759(02)00429-5
   PubMed Web of Science ®Google Scholar
• Vari F, Munster DJ, Hsu JL, Rossetti TR, Mahler SM, Gray PP, Turtle CJ, Prue RL, Hart DN. Practical blood dendritic cell vaccination for immunotherapy of multiple myeloma. Br J Haematol 2008; 143:374-7; PMID:18729856; http://dx.doi.org/10.1111/j.1365-2141.2008.07346.x
   PubMed Web of Science ®Google Scholar
• Sheikh NA, Jones LA. CD54 is a surrogate marker of antigen presenting cell activation. Cancer Immunol Immunother 2008; 57:1381-90; PMID:18297282; http://dx.doi.org/10.1007/s00262-008-0474-9
   PubMed Web of Science ®Google Scholar
• Wilson J, Cullup H, Lourie R, Sheng Y, Palkova A, Radford KJ, Dickinson AM, Rice AM, Hart DN, Munster DJ. Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease. J Exp Med 2009; 206:387-98; PMID:19171763; http://dx.doi.org/10.1084/jem.20070723
   PubMed Web of Science ®Google Scholar
• Wilkinson R, Woods K, D'Rozario R, Prue R, Vari F, Hardy MY, Dong Y, Clements JA, Hart DN, Radford KJ. Human kallikrein 4 signal peptide induces cytotoxic T cell responses in healthy donors and prostate cancer patients. Cancer Immunol Immunother 2012; 61:169-79; PMID:21874303; http://dx.doi.org/10.1007/s00262-011-1095-2
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-22; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294
   PubMed Web of Science ®Google Scholar
• Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18:3894-903; PMID:11099318
   PubMed Web of Science ®Google Scholar
• Burch PA, Breen JK, Buckner JC, Gastineau DA, Kaur JA, Laus RL, Padley DJ, Peshwa MV, Pitot HC, Richardson RL et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 2000; 6:2175-82; PMID:10873066
   PubMed Web of Science ®Google Scholar
• Hock BD, Fearnley DB, Boyce A, McLellan AD, Sorg RV, Summers KL, Hart DN. Human dendritic cells express a 95 kDa activation/differentiation antigen defined by CMRF-56. Tissue antigens 1999; 53:320-34; PMID:10323336; http://dx.doi.org/10.1034/j.1399-0039.1999.530402.x
   PubMedGoogle Scholar
• van de Laar L, Coffer PJ, Woltman AM. Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy. Blood 2012; 119:3383-93; PMID:22323450; http://dx.doi.org/10.1182/blood-2011-11-370130
   PubMed Web of Science ®Google Scholar
• Benlahrech A, Duraisingham S, King D, Verhagen L, Rozis G, Amjadi P, Ford T, Kelleher P, Patterson S. Human blood CD1c dendritic cells stimulate IL-12-independent IFN-gamma responses and have a strikingly low inflammatory profile. J Leukoc Biol 2015; 96:873-885; PMID:25765676; http://dx.doi.org/10.1189/jlb.1A0114-058RR
   PubMed Web of Science ®Google Scholar
• Sittig S, de Vries I, Schreibelt G. Primary human blood dendritic cells for cancer immunotherapy—tailoring the immune response by dendritic cell maturation. Biomedicines 2015; 3:282; http://dx.doi.org/10.3390/biomedicines3040282
   PubMed Web of Science ®Google Scholar
• Krebber A, Bornhauser S, Burmester J, Honegger A, Willuda J, Bosshard HR, Pluckthun A. Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system. J Immunol Methods 1997; 201:35-55; PMID:9032408; http://dx.doi.org/10.1016/S0022-1759(96)00208-6
   PubMed Web of Science ®Google Scholar
• Jones ML, Barnard RT. Chimerization of multiple antibody classes using splice overlap extension PCR. BioTechniques 2005; 38:181-2; PMID:15727121; http://dx.doi.org/10.2144/05382BM01
   PubMed Web of Science ®Google Scholar
• Vuckovic S, Fearnley DB, Mannering SI, Dekker J, Whyte LF, Hart DN. Generation of CMRF-44+ monocyte-derived dendritic cells: insights into phenotype and function. Experimental hematology 1998; 26:1255-64; PMID:9845382
   PubMed Web of Science ®Google Scholar
• Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E, Knop J, Enk AH. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997; 27:3135-42; PMID:9464798; http://dx.doi.org/10.1002/eji.1830271209
   PubMed Web of Science ®Google Scholar
• Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 2000; 60:1028-34; PMID:10706120
   PubMed Web of Science ®Google Scholar
• Hsu AK, Kerr BM, Jones KL, Lock RB, Hart DN, Rice AM. RNA loading of leukemic antigens into cord blood-derived dendritic cells for immunotherapy. Biol Blood Marrow Transplantation 2006; 12:855-67; PMID:16864056; http://dx.doi.org/10.1016/j.bbmt.2006.05.004
   PubMed Web of Science ®Google Scholar
• Lichtenfels R, Biddison WE, Schulz H, Vogt AB, Martin R. CARE-LASS (calcein-release-assay), an improved fluorescence-based test system to measure cytotoxic T lymphocyte activity. J Immunol Methods 1994; 172:227-39; PMID:7518485; http://dx.doi.org/10.1016/0022-1759(94)90110-4
   PubMed Web of Science ®Google Scholar
• Seldon TA, Pryor R, Palkova A, Jones ML, Verma ND, Findova M, Braet K, Sheng Y, Fan Y, Zhou EY et al. Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantation. Leukemia 2015; 30:692-700; PMID:26286117; http://dx.doi.org/10.1038/leu.2015.231
   PubMed Web of Science ®Google Scholar